#obesity

A newly approved daily weight-loss pill moved through U.S. FDA review faster than most drugs in recent years, signaling continued momentum in the obesity treatment market.

A prespecified analysis of the SELECT trial found semaglutide reduced major adverse cardiovascular events in patients at elevated risk of substantial liver fibrosis while also lowering fatty liver index versus placebo.

A landmark analysis finds that modifiable risk factors — smoking, obesity, alcohol, diet, and environmental exposures — account for a large and preventable share of the global cancer burden.

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Silicon Valley startup Twin Health is using continuous sensor data and artificial intelligence to build virtual replicas of patients' metabolisms, creating personalized treatment plans that have helped thousands reduce medications and reverse type 2 diabetes symptoms.

An oral compound from NTU Singapore reduces intestinal fat uptake and promotes beneficial gut bacteria without toxic side effects in animal models.